# Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Source: https://onco.cc/trials/nct07109219/  
OnCo record `nct07109219` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD4512 in acute lymphoblastic leukaemia, run by AstraZeneca, now recruiting.

## Summary

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT07109219 by AstraZeneca, with 83 participants planned, started 2025-11-12 and due to reach its primary completion in 2028-04-28. Interventions recorded: AZD4512 monotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07109219
- Phase: 1/2
- Setting: A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia
- Sponsor: AstraZeneca
- Enrolled: 83

## Sources

- ClinicalTrials.gov NCT07109219: https://clinicaltrials.gov/study/NCT07109219

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [AZD4512](https://onco.cc/drugs/azd4512/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Fortrea](https://onco.cc/companies/fortrea/)

---
JSON: https://onco.cc/api/v1/entities/nct07109219.json